ABAna Maria Badarau

Ana Maria Badarau

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Ana Maria Badarau has a total of 6 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Vocea tăcută a ficatului într-o boală sistemică. studiu de caz în sarcoidoza hepatică

    by Eugen Tcaciuc, Elina Berliba, Catalina Olaru-Stavila, Mariana Ous-Cebotar, Ana Maria Badarau

    Sarcoidosis is a systemic inflammatory disease of unknown etiology that may, in atypical cases, involve the liver. Hepatic manifestations are often subtle, heterogeneous, and nonspecific, which can mislead clinicians and delay an accurate diagnosis. Liver biopsy with histological examination remains the gold standard for diagnosis, playing a critical role in confirming hepatic sarcoidosis. We report the case of a 43-year-old female patient admitted to the hepatology department with persistent right upper quadrant pain and fatigue. Biochemical analysis revealed a cytolytic and cholestatic pattern, while complete blood count showed anemia and thrombocytosis. Viral, tumor, and autoimmune liver markers were within reference ranges. Abdominal ultrasound and computed tomography (CT) revealed hepatomegaly. Hematologic malignancies were ruled out. The diagnosis of hepatic sarcoidosis was established by histopathological examination of a liver biopsy. Considering the frequent association with pulmonary sarcoidosis, a thoracic CT scan was performe which revealed mediastinal lymphadenopathy. The patient was subsequently referred to the pulmonology team, where immunosuppressive therapy was initiated, with favorable clinical and laboratory evolution. This case highlights an unusual presentation of hepatic involvement in systemic sarcoidosis. It underscores the importance of a multidisciplinary approach to achieve timely diagnosis and initiate appropriate pathogenetic treatment, particularly in the presence of unexplained hepatic abnormalities.

  • A case report of primary hepatic amyloidosis manifesting as severe cholestasis and acute liver failure

    by Eugen Tcaciuc, Elina Berliba, Calina Bugor, Ruslan Pretula, Catalina Olaru-Stavila, Ana Maria Badarau

    Introduction. Hepatic amyloidosis is characterized by the deposition of fibrillar amyloid proteins, which result from light chain amyloidosis (AL) immunoglobulin fragments, in the extracellular space and the vessel walls of the liver. A case of primary hepatic amyloidosis without evidence of a primary or secondary cause of amyloid deposition is rare. This case was unique to the Republic of Moldova, presenting a diagnostic and therapeutic challenge for clinicians. Because the liver is rarely affected, this pathology remains underdiagnosed and is associated with a reserved prognosis. Clinical case presentation. An unusual case of primary hepatic amyloidosis is reported in a previously asymptomatic 59-year-old woman who presented at admission with peripheral edema, ascites, and hepatomegaly. Biochemical tests revealed severe cholestasis with normal bilirubin levels and acute liver failure. Liver damage caused by viral hepatitis or autoimmune diseases was excluded. A percutaneous bone marrow biopsy was normal, and Bence Jones protein was negative, indicating no evidence of primary amyloidosis. The definitive diagnosis was based on liver biopsy, which revealed apple green birefringence on polarizing microscopy after positive Congo red staining. Conclusions. The reported case highlights the need to differentiate between infiltrative diseases, such as amyloidosis, when a patient presents with rapidly progressive severe cholestasis and acute liver failure. Future studies should focus on the availability of specific therapies for primary amyloidosis to improve the survival rate of these patients.